Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis

Gastrointestinal Endoscopy

Volumn 69, Issue 4, 2009, Pages

  Choi, Cheol Woong ^a   Kang, Dae Hwan ^a   Kim, Gwang Ha ^a   Eum, Jae Sup ^a   Lee, Sun Mi ^a   Song, Geun Am ^a   Kim, Dong Uk ^a   Kim, Il Doo ^a   Cho, Mong ^a  

^a Pusan National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; GLUCOSE; IOPAMIDOL; NAFAMSTAT MESILATE; TRIACYLGLYCEROL LIPASE;

ABSENCE OF SIDE EFFECTS; ACUTE PANCREATITIS; ADULT; AGE DISTRIBUTION; AMYLASE BLOOD LEVEL; ARTICLE; CANNULATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DIVERTICULOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PANCREAS DUCT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TERTIARY HEALTH CARE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DOUBLE-BLIND METHOD; FEMALE; GUANIDINES; HUMANS; MALE; MIDDLE AGED; PANCREATITIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 62749092576     PISSN: 00165107     EISSN: 10976779     Source Type: Journal    
DOI: 10.1016/j.gie.2008.10.046     Document Type: Article

References (41)

1. Andriulli A., Loperfido S., Napolitano G., et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol 102 (2007) 1781-1788
2. Freeman M.L., and Guda N.M. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 59 (2004) 845-864
3. Singh P., Das A., Isenberg G., et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc 60 (2004) 544-550
4. Pezzilli R., Romboli E., Campana D., et al. Mechanisms involved in the onset of post-ERCP pancreatitis. JOP 3 (2002) 162-168
5. Manes G., Ardizzone S., Lombardi G., et al. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. Gastrointest Endosc 65 (2007) 982-987
6. Andriulli A., Leandro G., Federici T., et al. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc 65 (2007) 624-632
7. Andriulli A., Leandro G., Niro G., et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 51 (2000) 1-7
8. Cavallini G., Tittobello A., Frulloni L., et al. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy: Italian Group. N Engl J Med 335 (1996) 919-923
9. Masci E., Cavallini G., Mariani A., et al. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. Am J Gastroenterol 98 (2003) 2182-2186
10. Zheng M., Bai J., Yuan B., et al. Meta-analysis of prophylactic corticosteroid use in post-ERCP pancreatitis. BMC Gastroenterol 8 (2008) 6
11. Barkay O., Niv E., Santo E., et al. Low-dose heparin for the prevention of post-ERCP pancreatitis: a randomized placebo-controlled trial. Surg Endosc 22 (2008) 1971-1976
12. Elmunzer B.J., Waljee A.K., Elta G.H., et al. A meta-analysis of NSAIDs in the prevention of post-ERCP pancreatitis. Gut 57 (2008) 1262-1267
13. Murray B., Carter R., Imrie C., et al. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 124 (2003) 1786-1791
14. Sotoudehmanesh R., Khatibian M., Kolahdoozan S., et al. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am J Gastroenterol 102 (2007) 978-983
15. Romagnuolo J., Hilsden R., Sandha G.S., et al. Allopurinol to prevent pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized placebo-controlled trial. Clin Gastroenterol Hepatol 6 (2008) 465-471 quiz 371
16. Keck T., Balcom J.H., Antoniu B.A., et al. Regional effects of nafamostat, a novel potent protease and complement inhibitor, on severe necrotizing pancreatitis. Surgery 130 (2001) 175-181
17. Mizuguchi T., Mukaiya M., Imaizumi H., et al. Successful management of severe acute pancreatitis with multiple organ failure. Pancreas 28 (2004) 211-213
18. Cheng C.L., Sherman S., Watkins J.L., et al. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol 101 (2006) 139-147
19. Cotton P.B., Lehman G., Vennes J., et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 37 (1991) 383-393
20. WHO/IASO/IOTF. The Asian-Pacific perspective: redefining obesity and its treatment (2000), WHO Western Pacific Region, Geneva, Switzerland
21. Messmann H., Vogt W., Holstege A., et al. Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis. Gut 40 (1997) 80-85
22. Poon R.T., Yeung C., Lo C.M., et al. Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc 49 (1999) 593-598
23. Manolakopoulos S., Avgerinos A., Vlachogiannakos J., et al. Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. Gastrointest Endosc 55 (2002) 470-475
24. Katsinelos P., Kountouras J., Chatzis J., et al. High-dose allopurinol for prevention of post-ERCP pancreatitis: a prospective randomized double-blind controlled trial. Gastrointest Endosc 61 (2005) 407-415
25. Rabenstein T., Fischer B., Wiessner V., et al. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc 59 (2004) 606-613
26. Deviere J., Le Moine O., Van Laethem J.L., et al. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 120 (2001) 498-505
27. Dumot J.A., Conwell D.L., Zuccaro Jr. G., et al. A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis. Am J Gastroenterol 96 (2001) 2098-2102
28. Andriulli A., Clemente R., Solmi L., et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 56 (2002) 488-495
29. Thomopoulos K.C., Pagoni N.A., Vagenas K.A., et al. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis. Gastrointest Endosc 64 (2006) 726-731
30. Li Z.S., Pan X., Zhang W.J., et al. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: a multicenter, placebo-controlled, randomized clinical trial. Am J Gastroenterol 102 (2007) 46-51
31. Yoshikawa T., Murakami M., Furukawa Y., et al. Effects of FUT-175, a new synthetic protease inhibitor on endotoxin-induced disseminated intravascular coagulation in rats. Haemostasis 13 (1983) 374-378
32. Mori S., Itoh Y., Shinohata R., et al. Nafamostat mesilate is an extremely potent inhibitor of human tryptase. J Pharmacol Sci 92 (2003) 420-423
33. Freeman M.L., DiSario J.A., Nelson D.B., et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 54 (2001) 425-434
34. Aronson N., Flamm C.R., Bohn R.L., et al. Evidence-based assessment: patient, procedure, or operator factors associated with ERCP complications. Gastrointest Endosc 56 (2002) S294-S302
35. Freeman M.L. Post-ERCP pancreatitis: patient and technique-related risk factors. JOP 3 (2002) 169-176
36. Masci E., Mariani A., Curioni S., et al. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis. Endoscopy 35 (2003) 830-834
37. Rabenstein T., Schneider H.T., Bulling D., et al. Analysis of the risk factors associated with endoscopic sphincterotomy techniques: preliminary results of a prospective study, with emphasis on the reduced risk of acute pancreatitis with low-dose anticoagulation treatment. Endoscopy 32 (2000) 10-19
38. Vandervoort J., Soetikno R.M., Tham T.C., et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc 56 (2002) 652-656
39. Sherman S., and Lehman G.A. ERCP- and endoscopic sphincterotomy-induced pancreatitis. Pancreas 6 (1991) 350-367
40. Laugier R., Bernard J.P., Berthezene P., et al. Changes in pancreatic exocrine secretion with age: pancreatic exocrine secretion does decrease in the elderly. Digestion 50 (1991) 202-211
41. Cohen S., Bacon B.R., Berlin J.A., et al. National Institutes of Health State-of-the-Science Conference Statement: ERCP for diagnosis and therapy, January 14-16, 2002. Gastrointest Endosc 56 (2002) 803-809